samedan logo

 
 
spacer
home > white papers > CRSF Label - Child-Resistant Blister Packs With Booklet Label - Faubel & Co. Nachfolger GmbH
WHITE PAPERS
logo_Faubel_&_C3.JPG

Faubel & Co. Nachfolger GmbH

phone +49 5661 7309-0
email info@faubel.de
web http://www.faubel.de
email Schwarzenberger Weg 45, 34212 Melsungen

CRSF Label - Child-Resistant Blister Packs With Booklet Label

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.

The project was primarily focused on the functionality of the packaging solution, including with regard to the integrity of the inner soft capsules. Due to different countries participating in the clinical trial, the objective was to achieve certification according to EU standard DIN 14375 and US standard 16 CFR § 1700.20 with the final concept as well as to accommodate more than 20 different languages. Despite the high requirements in terms of function and the standard, Faubel was anxious to provide an efficient packaging concept.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>


White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>


Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement